Bedaquiline belongs to the therapeutic class of antimycobacterial agents. It was approved by the FDA in 2012 for the treatment of multidrug-resistant tuberculosis (MDR-TB).

In a 2016 Phase 2 study, the safety and efficacy of Bedaquiline for treating multidrug-resistant tuberculosis (MDR-TB) were assessed. The study found that combining Bedaquiline with a background regimen significantly improved treatment outcomes, highlighting its potential as a key component in managing drug-resistant TB. 

Bedaquiline is used as part of combination therapy to treat multidrug-resistant pulmonary tuberculosis in adults when other alternatives are not sufficient.

Bedaquiline is administered orally, usually in combination with other TB medications. The dose and duration depend on the patient's condition and their response to treatment. It is essential to follow the prescribed regimen closely.

Common side effects include nausea, joint pain, headache, and dizziness. Serious effects like QT prolongation and liver toxicity can occur and need monitoring.

Bedaquiline should not be used as monotherapy due to the risk of resistance. QT prolongation has been observed, and its use requires ECG monitoring.

Bedaquiline should be used cautiously by patients with a history of heart conditions or those taking other drugs that affect heart rhythm.

Take Bedaquiline with food to enhance absorption. It is crucial to complete the entire course of therapy and not miss doses, as this can lead to treatment failure and resistance. Avoid alcohol and monitor liver function during treatment. Always consult your doctor for any concerns.

1. https://pubchem.ncbi.nlm.nih.gov/compound/Bedaquiline
2. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/bedaquiline
3. KD Tripathi, Essentials of Medical Pharmacology, Antiemetic, Prokinetic and Digestant Drugs, 7th edition, 2013, 669-670. 

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.